Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2018 1
2019 1
2020 1
2021 9
2022 7
2023 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model.
Yadav PD, Mohandas S, Shete A, Sapkal G, Deshpande G, Kumar A, Wakchaure K, Dighe H, Jain R, Ganneru B, Yemul J, Gawande P, Vadrevu KM, Abraham P. Yadav PD, et al. Among authors: vadrevu km. iScience. 2022 Oct 21;25(10):105178. doi: 10.1016/j.isci.2022.105178. Epub 2022 Sep 22. iScience. 2022. PMID: 36164480 Free PMC article.
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®).
Singh C, Verma S, Reddy P, Diamond MS, Curiel DT, Patel C, Jain MK, Redkar SV, Bhate AS, Gundappa V, Konatham R, Toppo L, Joshi AC, Kushwaha JS, Singh AP, Bawankule S, Ella R, Prasad S, Ganneru B, Chiteti SR, Kataram S, Vadrevu KM. Singh C, et al. Among authors: vadrevu km. NPJ Vaccines. 2023 Aug 18;8(1):125. doi: 10.1038/s41541-023-00717-8. NPJ Vaccines. 2023. PMID: 37596281 Free PMC article.
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Vadrevu KM, Ganneru B, Reddy S, Jogdand H, Raju D, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai SK, Ella R, Abraham P, Prasad S, Ella K. Vadrevu KM, et al. Sci Rep. 2022 Jul 14;12(1):12038. doi: 10.1038/s41598-022-16097-3. Sci Rep. 2022. PMID: 35835822 Free PMC article. Clinical Trial.
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.
Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, Vadrevu KM, Bhati G, Sapkal G, Kaushal H, Patil S, Jain R, Deshpande G, Gupta N, Agarwal K, Gokhale M, Mathapati B, Metkari S, Mote C, Nyayanit D, Patil DY, Sai Prasad BS, Suryawanshi A, Kadam M, Kumar A, Daigude S, Gopale S, Majumdar T, Mali D, Sarkale P, Baradkar S, Gawande P, Joshi Y, Fulari S, Dighe H, Sharma S, Gunjikar R, Kumar A, Kalele K, Srinivas VK, Gangakhedkar RR, Ella KM, Abraham P, Panda S, Bhargava B. Yadav PD, et al. Among authors: vadrevu km. Nat Commun. 2021 Mar 2;12(1):1386. doi: 10.1038/s41467-021-21639-w. Nat Commun. 2021. PMID: 33654090 Free PMC article.
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants.
P KK, Chiteti SR, Aileni VK, Babji S (late), Blackwelder WC, Kumar A, Vagha J, Nayak U, Mitra M, D N, Kar S, Yadav S, Naidu S, Mahantshetti N, Khalatkar V, Mohapatra S, Purthi PK, Sharma P, Kannan A, Dhongade RK, Prasad SD, Ella R, Vadrevu KM. P KK, et al. Among authors: vadrevu km. Hum Vaccin Immunother. 2023 Dec 15;19(3):2278346. doi: 10.1080/21645515.2023.2278346. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37968237 Free PMC article. Clinical Trial.
Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children.
Vadrevu KM, Dugyala R, Mahantashetti NS, Khalatkar V, Murthy K, Mogre S, Mitra M. Vadrevu KM, et al. Hum Vaccin Immunother. 2022 Dec 30;18(7):2150030. doi: 10.1080/21645515.2022.2150030. Epub 2022 Dec 7. Hum Vaccin Immunother. 2022. PMID: 36476258 Free PMC article. Clinical Trial.
Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern.
Deshpande GR, Yadav PD, Abraham P, Nyayanit DA, Sapkal GN, Shete AM, Gupta N, Vadrevu KM, Ella R, Panda S, Bhargava B. Deshpande GR, et al. Among authors: vadrevu km. J Travel Med. 2022 May 31;29(3):taac039. doi: 10.1093/jtm/taac039. J Travel Med. 2022. PMID: 35325176 No abstract available.
24 results